Browsing Tag
FSGS
3 posts
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI
Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market.
Dimerix stock up 74% YTD as FSGS asset DMX-200 gets safety green light
Dimerix’s FSGS drug candidate DMX-200 clears key Phase 3 safety review with no concerns. Learn how this ASX biotech aims to reshape kidney disease treatment.